Skip to content
Open access

Salvage treatment incorporating arsenic trioxide for pediatric relapsed acute lymphoblastic leukemia: a retrospective real-world analysis

Nov 2026 · Frontiers in Oncology · 0 citations · 33 references

Abstract

Relapsed pediatric acute lymphoblastic leukemia (ALL) confers an unfavorable prognosis. We evaluated the outcomes of an arsenic trioxide (ATO)-incorporating chemotherapy protocol in pediatric first-relapsed ALL. Patients were risk-stratified according to the ALL-REZ BFM 2002 protocol. Group A received an institutional ATO-containing protocol at one university-affiliated hospital between September 2010 and September 2021, while Group B followed the ALL-REZ BFM 2002 protocol at another one in the same city during the similar period. Group A comprised 43 patients, 9 high-risk, among whom one (11.1%) underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT). Group B had 35 patients with 15 high-risk among whom 7 (46.7%) received allo-HSCT. In non-high-risk patients, 5-year event-free survival (EFS) was comparable between groups (73.5% vs 70.0%, P  = 0.794). Among high-risk patients, EFS was higher in Group A (44.4% vs 13.3%, P  = 0.048). Moreover, Group A remained independently associated with better EFS in a multivariable Cox model incorporating allo-HSCT as a time-dependent covariate (HR = 0.50, 95% CI: 0.25-0.99, P  = 0.048). High-risk relapsed ALL stratified by the ALL-REZ BFM 2002 stratification system carries a poor prognosis. The incorporation of ATO into salvage regimens merits further investigation, and prospective randomized controlled trials would help confirm its promising prognostic advantages.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.